ArticleCurrent cardiology reviews2017
Current State of Bioabsorbable Polymer-Coated Drug-Eluting Stents.
Article in Current cardiology reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The effect of exosome-related therapy in cardiac revascularization procedures: a systematic review.BMC cardiovascular disorders · 2025Pooled it
- Biodegradable polymer everolimus-eluting stents versus contemporary drug-eluting stents: a systematic review and meta‑analysis.Scientific reports · 2023Pooled it
- Auxetic Stents as a Next Generation Solution for Vascular Diseases-A Review.Cardiovascular engineering and technology · 2026Review
- Development of Biodegradable and Biobased Poly(glycerol levulinate-Macromolecules · 2025Article
- Recurrent subacute stent thrombosis after drug-eluting stent implantation: a case report.BMC cardiovascular disorders · 2025Article
- Two-Staged Technology for CoCr Stent Production by SLM.Materials (Basel, Switzerland) · 2024Article
- Global trends in clinical trials involving engineered biomaterials.Science advances · 2024Review
- Polymer-Drug Anti-Thrombogenic and Hemocompatible Coatings as Surface Modifications.Pharmaceutics · 2024Review
- Coatings for Cardiovascular Stents-An Up-to-Date Review.International journal of molecular sciences · 2024Review
- Optimize PLA/EVA Polymers Blend Compositional Coating for Next Generation Biodegradable Drug-Eluting Stents.Polymers · 2022Article
- Evolutionary perspective of drug eluting stents: from thick polymer to polymer free approach.Journal of cardiothoracic surgery · 2022Review
- Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population-12-Month Clinical Outcome.Journal of interventional cardiology · 2022Article
- Use of 3D Printing for the Development of Biodegradable Antiplatelet Materials for Cardiovascular Applications.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Evolution of drug-eluting biomedical implants for sustained drug delivery.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2021Review
- The Use of Bioactive Polymers for Intervention and Tissue Engineering: The New Frontier for Cardiovascular Therapy.Polymers · 2021Review
- Bioresorbable Polymeric Scaffold in Cardiovascular Applications.International journal of molecular sciences · 2020Review
- Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering.Frontiers in pharmacology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-eluting stents (DES) have been shown to significantly reduce clinical and angiographic restenosis compared to bare metal stents (BMS). The polymer coatings on DES elute antiproliferative drugs to inhibit intimal proliferation and prevent restenosis after stent implantation. Permanent polymers which do not degrade in vivo may increase the likelihood of stent-related delayed arterial healing or polymer hypersensitivity. In turn, these limitations may contribute to an increased risk of late clinical events. Intuitively, a polymer which degrades after completion of drug release, leaving an inert metal scaffold in place, may improve arterial healing by removing a chronic source of inflammation, neoatherosclerosis, and/or late thrombosis. In this way, a biodegradable polymer may reduce late ischemic events. Additionally, improved healing after stent implantation could reduce the requirement for long-term dual antiplatelet therapy and the associated risk of bleeding and cost. This review will focus on bioabsorbable polymer-coated DES currently being evaluated in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.